The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | Managing anemia in MDS & MPNs: the value of a multidisciplinary approach
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, briefly discusses the significance of anemia in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), highlighting the need for a multidisciplinary approach to manage anemia and develop targeted therapies. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we had a symposium yesterday at SOHO, a pre-SOHO symposium hosted by Guillermo Garcia Manero and myself with a huge panel of experts in MDS, MPN, and then allied co-workers like pathologists and transfusion medicine docs and cardiologists and community oncologists for a multidisciplinary discussion on the significance of anemia. I think it’s a fascinating topic because anemia is both part and parcel and a object or target of therapeutic intervention for both MDS and MPNs and myelofibrosis specifically...
So we had a symposium yesterday at SOHO, a pre-SOHO symposium hosted by Guillermo Garcia Manero and myself with a huge panel of experts in MDS, MPN, and then allied co-workers like pathologists and transfusion medicine docs and cardiologists and community oncologists for a multidisciplinary discussion on the significance of anemia. I think it’s a fascinating topic because anemia is both part and parcel and a object or target of therapeutic intervention for both MDS and MPNs and myelofibrosis specifically. There’s a lot of disease biology that overlaps, but yet there are distinctions between these diseases. And there are many therapies that are in development or approved in MDS like luspatercept that are still being evaluated in myelofibrosis. So there’s a lot that we can learn from both disease types and from physicians that treat both and many physicians treat both that have expertise in this area. So it was a nice opportunity for us as a wider group to get together with a focus on anemia but coming at it from different angles of myelodysplastic syndrome, ineffective blood cell development or myelofibrosis which is also a state of bone marrow failure but the mechanisms may differ and how to develop therapies that make more sense and how to practically manage our patients in a multidisciplinary approach.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
